Staquet M J
Curr Med Res Opin. 1980;6(7):475-7. doi: 10.1185/03007998009109471.
A double-blind, crossover study was carried out in 15 patients with chronic pain due to cancer to assess the effectiveness of two different doses of a new analgesic, ciramadol, compared with placebo. Patients received single oral doses of the three medications, in random order, on successive days. Assessments of pain intensity and relief were made on a 4-point rating scale at hourly intervals for 4 hours after the dose. The results showed that ciramadol produced significantly more pain relief than did placebo and this analgesic effect increased with the dose administered. Peak activity was observed at about 2 hours, and pain relief was still marked at 4 hours. No side-effects were reported.
对15名因癌症引起慢性疼痛的患者进行了一项双盲交叉研究，以评估两种不同剂量的新型镇痛药环拉马多与安慰剂相比的有效性。患者连续数天按随机顺序单次口服这三种药物。给药后4小时内，每隔1小时用4分制评分量表对疼痛强度和缓解情况进行评估。结果显示，环拉马多产生的疼痛缓解明显多于安慰剂，且这种镇痛效果随给药剂量的增加而增强。在约2小时时观察到峰值活性，4小时时疼痛缓解仍很明显。未报告有副作用。
